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Resistance to thyroid hormone alpha (RTHa) is characterised by
tissue-speciﬁc hypothyroidism associated with near-normal thy-
roid function tests. Clinical features include dysmorphic facies,
skeletal dysplasia (macrocephaly, epiphyseal dysgenesis), growth
retardation, constipation, dyspraxia and intellectual deﬁcit.
Biochemical abnormalities include low/low-normal T4 and high/
high-normal T3 concentrations, a subnormal T4/T3 ratio, variably
reduced reverse T3, raised muscle creatine kinase and mild
anaemia.
The disorder is mediated by heterozygous, loss-of-function, mu-
tations involving either TRa1 alone or both TRa1 and a2, with no
discernible phenotype attributable to defective a2. Whole exome
sequencing and diagnostic biomarkers may enable greater ascer-
tainment of RTHa, which is important as thyroxine therapy re-
verses some metabolic abnormalities and improves growth,
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Summary of some major physiological actions of th
Actions of thyroid hormone
Tissue Action
Brain Cortical & cerebellar d
Liver Lower cholesterol
Raises SHBG
Myocardium Positive inotropic and
Hypothalamus Inhibits TRH secretion
Pituitary Inhibits TSH secretion
Multiple Increases basal metaboThe genetic and phenotypic heterogeneity of RTHa and its optimal
management remain to be elucidated.
© 2015 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).Introduction
The diverse physiological actions of thyroid hormones (TH: thyroxine, T4; triiodothyronine, T3)
include regulation of growth, control of metabolic rate, positive chronotropic and inotropic cardiac
effects and development of the central nervous system (Table 1). TH synthesis is controlled by hypo-
thalamic thyrotropin-releasing hormone (TRH) and pituitary thyroid stimulating hormone (TSH) and,
in turn, T4 and T3 regulate TRH and TSH synthesis as part of a negative feedback loop. These physi-
ological effects are mediated by thyroid hormone-dependent changes in expression of speciﬁc target
genes in different tissues (Table 1). The cellular entry of thyroid hormones , particularly in the central
nervous system, is mediated by a membrane transporter [monocarboxylate transporter 8 (MCT8)] [1].
Intracellularly, deiodinase enzymes (DIOs) mediate hormone metabolism, with a high-afﬁnity type 2
enzyme (DIO2) mediating T4 to T3 conversion in the central nervous system (CNS) including pituitary
and hypothalamus, type I deiodinase (DIO1) generating T3 in peripheral tissues, and type 3 deiodinase
(DIO3) mediating catabolism of thyroid hormones to inactive metabolites [2]. Thyroid hormones alter
target gene expression via a receptor protein (TR), belonging to the steroid/nuclear receptor super-
family of ligand-inducible transcription factors. TR binds preferentially to regulatory DNA sequences
(thyroid hormone response elements, TREs) in target gene promoters as a heterodimer with the
retinoid X receptor (RXR), although the receptor can bind some TREs as a homodimer or monomer. In
the absence of hormone, unliganded receptor homodimers/heterodimers recruit a protein complex
containing corepressors (e.g. nuclear receptor corepressor [NCoR]; silencing mediator for retinoic acid
and thyroid receptors [SMRT]) and histone deacetylase (HDAC) to repress basal gene transcription.
Receptor occupancy by hormone (T3) results in dissociation of the corepressor complex and relief of
repression together with recruitment of coactivator proteins which mediate transcriptional activation
[3].
In humans, two highly homologous thyroid hormone receptors, TRa and TRb are encoded by
genes (THRA, THRB) on chromosomes 17 and 3, respectively. Two different proteins are generated
from the THRA locus by alternate splicing: TRa1 is an ubiquitously expressed receptor isoform, with
particular abundance in the central nervous system, myocardium, gastrointestinal tract and skeletal
muscle; a2 protein, which exhibits a divergent carboxy-terminal region such that it is unable to
bind thyroid hormones (Fig. 1), is expressed in a variety of tissues (e.g. brain and testis) and its
biological function is poorly understood [4]. The REV-ERBa gene, located on the opposite strand of
the THRA locus, is transcribed to generate a nuclear receptor which is involved in regulating
circadian rhythm [5]. THRB generates two major receptor isoforms, TRb1 and TRb2, which differ in
their amino-terminal regions; TRb1, which is widely expressed, is the predominant isoform in liveryroid hormone in tissues and associated target genes.
Target genes
evelopment; myelination Krüppel-like factor 9; Hairless;
Myelin basic protein
LDL receptor
SHBG
chronotropic effect a- myosin heavy chain
Sarcoplasmic Ca2þ-ATPase
Pro-thyrotrophin releasing hormone
TSH a and b subunits
lic rate Multiple
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Fig. 1. Schematic illustrating the domain structure of proteins derived from the sense strand of THRA locus, together with the
location of known mutations. Thyroid hormone receptor a1 (TRa1) and the splice variant protein a2 aligned by their DNA binding
domains (DBD), which are identical. The ligand binding domains are coloured in grey, with non homologous areas shaded. The
location of each known TRa mutation is depicted; only A263V and N359Y affect both TRa1 and a2 transcripts; the remainder of the
mutations only affect TRa1.
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and retina [4].
Resistance to Thyroid Hormone beta (RTHb), a dominantly-inherited disorder due to THRB muta-
tions, is readily recognized due to a characteristic biochemical signature of elevated circulating T4 and
T3 with non-suppressed pituitary TSH levels reﬂecting central (hypothalamicepituitary) refractoriness
to thyroid hormone action and is associated with variable resistance to hormone action in peripheral
tissues [6]. The incidence of RTHb is ~1 in 40,000, and several hundred heterozygous, b receptor
mutations which localise to three hotspots or clusters within its ligand binding domain (LBD) have
been identiﬁed in this disorder [7]. Consistent with its mode of inheritance, mutant b receptors in RTHb
inhibit the function of their wild type receptor counterparts in a dominant negative manner; consti-
tutive target gene repression due to failure of corepressor complex dissociation from mutant TRb
represents a likely mechanism for such dominant negative inhibition [8].
Human TRb and TRa exhibit marked aminoacid sequence similarity, including (80%) in their hor-
mone binding domains; accordingly, with ~160 different receptor mutations known to be associated
with RTHb, the identiﬁcation of a homologous human disorder with defective TRa had been antici-
pated. Supporting this notion, murine transgenic models harbouring different, heterozygous, TRa
mutations are viable and exhibit recognisable abnormalities, but with little perturbation of thyroid
function [9e12]; such absence of an overt biochemical, thyroid, phenotype likely explains why the
homologous human disorder had eluded discovery. However, human THRA mutations have now been
identiﬁed in 14 cases from 10 different families, with hypothyroid features and thyroid hormone
resistance in target tissues, but associated paradoxically with near-normal thyroid function tests
[13e20]. Here, we review the clinical features, differential diagnosis, molecular genetics, pathogenesis
and management of Resistance to Thyroid Hormone due to defective thyroid receptor alpha (RTHa).
Clinical features
At birth, some features (e.g. macroglossia, poor feeding, hoarse cry), recognized in hypothyroidism,
have been noted [16,17]. Several patients were investigated in infancy for growth retardation which in
some cases predominantly affected the lower segment [13,18]. Abnormal physical characteristics in the
majority of cases include macrocephaly, broad facies, hypertelorism, a ﬂattened nose, prominent
tongue and thick lips [13e18]; indeed, ﬁve cases were identiﬁed following genetic investigation of a
clinic patient cohort with these shared characteristics [18]. An excessive number of skin tags andmoles
have been noted, particularly in adults [13,16,17].
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Themost consistent pattern of thyroid function tests comprises low or low-normal free T4, and high
or high-normal free T3, resulting in an abnormally low T4/T3 ratio; reverse T3 levels were subnormal in
severe cases [13e17] but can be normal [19,20]. A mild, usually normocytic anaemia [13,15e18] with
normal haematinics (Iron, B12, folate) and haemolytic indices (reticulocyte count, circulating hapto-
globin and lactate dehydrogenase) [16] and raised muscle creatine kinase levels [13,15e17] are a
consistent abnormality. Raised total and LDL cholesterol levels have been documented [15,16], even in
childhood cases.Skeletal
Radiographic abnormalities in childhood include delayed fontanelle fusion and excessively
serpiginous cranial sutures (“wormian bone” appearance), together with delayed dentition [13,14];
femoral epiphyseal dysgenesis was present in childhood [13,18] but not in adult life [16]; bone age can
be delayed [13,14,18]. A thickened calvarium (skull vault) and cortical hyperostosis in long bones,
together with increased bone mineral density, is present in most cases, especially adults.Neurocognitive
In childhood, patients showed delayed milestones (motor, speech). Slow initiation of motor
movement, together with ﬁne and gross motor incoordination, manifesting as dyspraxia or a broad-
based, ataxic gait and slow, dysarthric speech were a consistent feature. Their IQ was variably
reduced, being markedly subnormal, with seizures in one case [16].Gastrointestinal
Reduced frequency of bowel movements is a common ﬁnding, with severe constipation being a
signiﬁcant problem in several cases [13,16,18].Cardiovascular
Bradycardia [13,16,17] is typical, with abnormal sympathovagal balance and indices of cardiac
contractility in the hypothyroid range [16].Metabolic & endocrine
Resting energy expenditure (metabolic rate) was low in most patients [13,16,17,19]. Both male and
female to offspring transmission of TRa defects has been recorded [14,17,18], suggesting that fertility in
either gender is not unduly compromised.
Table 2 summarises known clinical features of RTHa, together with clinical, biochemical and
physiological investigations which can identify recognised abnormalities.
Differential diagnosis
RTHa could be suspected in childhood patients with dysmorphic features or retardation of
growth and psychomotor development or adults with a history of such features. Whilst a low ratio
of circulating T4/T3 levels is a consistent feature which could identify potential cases, this
biochemical abnormality is also a feature of disorders (genetic or environmental) with dyshor-
monogenetic hypothyroidism or AllaneHerndoneDudley syndrome due to defects in the MCT8
gene. Table 3 shows clinical and biochemical features which could differentiate between these
entities.
Table 2
Summary of clinical features and suggested investigations for resistance to thyroid hormone alpha.
System Clinical feature/phenotype Investigations and possible ﬁndings
Appearance  Flattened nasal bridge
 Broad face, thickened lipsa
 Macroglossiaa
 Coarse facies, skin tags and molesa
 Dysmorphology
Skeletal  Disproportionate short staturea
 Macrocephalya
 Delayed tooth eruptiona
 Auxology: reduced total height, normal sitting height but
reduced subischial leg length, increased head circumference
for age (children) or height (adults). Weight or BMI may
be increased.
 Skull radiograph: thickened calvarium, delayed fontanelle
fusion,b excessively serpiginous lambdoid suture
(Wormian bones)b
 Pelvic and long bone radiographs: Cortical hyperostosis,
femoral epiphyseal dysgenesisb
 Spine radiograph: Scalloped vertebral bodies
 Dental radiograph: Delayed tooth eruption
 Bone age radiograph: Delayed carpal bone maturationb
 DXA scan or quantitative CT: increased bone mineral
density at hip
Gastrointestinal  Constipationa  Abdominal radiograph: dilated bowel loops and
impacted faecal matter
 Colonic manometry: reduced peristalsis
Cardiovascular  Bradycardia
 Low blood pressure for age
and gender
 Cardiac telemetry: reduced average sleeping heart rate
 Spectral analysis of cardiac autonomic tone: increased
parasympathetic (vagal) tone
 Echocardiography: hypothyroid indices of contractility
Metabolic  Low metabolic ratea
 Borderline abnormal thyroid
function testsa
 Indirect calorimetry: reduced resting energy expenditure
 Creatine kinase- skeletal muscle isoenzyme (MM): raised
 Lipid proﬁles: raised total and LDL cholesterol
 SHBG: raised or normal
 ft4/fT3 ratio: low or low normal
 Reverse T3: low or normal
 IGF-1: low or normal
Haematological  Mild anaemia  Full blood count: low red cell mass or haematocrit with
normal MCV and normal B12, folate, reticulocyte count
Neurological &
cognitive
 Delayed developmental
milestones
 Slow, dysarthric speecha
 Slow initiation of movement,
ataxic gait
 Dysdiadochokinesis
 Fine and gross motor
incoordination (dyspraxia)a
 Seizures
 ? Autism spectrum disorder
 MRI brain: microcephaly and reduced cerebellar size
 Neuropsychological testing: reduced IQ, low visual,
verbal and working memory scores, reduced motor
coordination
a Indicates features found in the majority of patients.
b Indicates radiological features found in children only.
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Affected individuals are heterozygous for THRA mutations which occurred de novo in six cases
[13,18e20] or were familial [14,17,18]. Hitherto, two broad classes of receptor defect have been iden-
tiﬁed: either highly deleterious, frameshift/premature stop mutations; or less severe, missense, ami-
noacid changes (Fig. 1). None of the mutations affect the REV-ERBa gene, transcribed from the opposite
strand of the THRA locus.
Most cases harbour mutations which selectively disrupt the carboxyterminal activation domain of
TRa1 [13,14,17,18]. Consistent with this, where their functional properties have been elucidated, the
mutant receptors fail to bind ligand and are devoid of transcriptional activity [13,15,16]. Similar to TRb
mutations in RTHb, TRa1 mutants inhibit the function of their wild type receptor counterparts in a
Table 3
Differential diagnosis of disorders with a high T3, low T4, normal TSH pattern of thyroid function tests.
Disorder Dyshormonogenesis Resistance to thyroid
hormone a
Allan Herndon Dudley
syndrome
Genetic e congenital
hypothyroidism
Environmental e iodine
deﬁciency
fT4 Normal or low Normal or low Normal or low Normal or low
fT3 Normal or raised Raised Raised Raised
fT4/fT3 Ratio Low Low Low Low
TSH Normal or raised Normal Normal Normal
Reverse T3 Normal Normal Normal or low Low
Thyroglobulin Raised Raised Normal Normal
Urinary iodine Normal Low Normal Normal
Clinical features Goitre Goitre Growth retardation Mental & psychomotor
retardation
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constitutive binding of mutant TR to corepressors, with failure of corepressor dissociation and coac-
tivator recruitment following T3 occupancy, likely mediates dominant negative inhibition (Fig. 2).
Expression of TH-responsive target genes in mutation-containing patient peripheral bloodA
TARGET GENE TRE
RXR TR
-ve
HDAC
CoR
Wild Type Receptor Mutant Receptor
C
CoR
T3
B
TARGET GENE TRE
RXR TR
+ve
HDACCoA
T3
T3
D
TARGET GENE TRE
RXR TR
-ve
HDAC
CoR
TARGET GENE TRE
RXR TR
-ve
HDAC
CoR
Fig. 2. Model of transcriptional regulation of target genes by thyroid receptors (TR). Unliganded TRs [usually bound as a heterodimer
with retinoid X receptor (RXR) to speciﬁc regulatory segments in the target gene (thyroid hormone response elements; TREs)]
recruit a corepressor complex (CoR) including histone deacetylase (HDAC), which acts to inhibit gene transcription (Panel A). Re-
ceptor occupancy by T3 (Panel B) promotes dissociation of the corepressor complex and recruitment of a coactivator complex (CoA),
mediating activation of target gene transcription. Mutant TRs can recruit the CoR complex and inhibit basal gene transcription (Panel
C) but are unable to bind T3 and hence cannot release the CoR complex or recruit CoA, resulting in persistent inhibition of gene
transcription, even in the presence of hormone (Panel D).
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[13,16,17,19].
In one family, three affected individuals harbored a missense mutation (A263V) in THRA, which
affects both TRa1 and a2 proteins [17]. Furthermore, this aminoacid change in TRa1 is homologous to a
TRb mutation (A317V) recognized to mediate RTHb, with that TRb mutation localising to one of the
mutation clusters within its ligand binding domain. The A263V TRa1 mutant was transcriptionally
impaired at low T3 concentrations, but higher TH levels restored mutant receptor function and
reversed its dominant negative inhibitory activity. In the a2 protein background, the A263V mutation
exhibited no added gain or loss-of-function; this is consistent with the uncertain functional role of
normal a2 and previous observations suggesting that it is unable to heterodimerise with RXR, bind
TREs or exert dominant negative activity via corepressor recruitment [21e23]. Such absence of altered
mutant a2 function correlated with the observation that patients with the combined TRa1 and a2
mutation had no discernible extra phenotypes, attributable to A263V mutant a2 [17].
A 27yr old female, harboring a de novo mutation (N359Y) affecting both TRa1 and a2 proteins,
exhibited a low FT4/FT3 ratio but other features (micrognathia, clavicular agenesis, hypoplasia,
metacarpal fusion and syndactyly of digits, hyperparathyroidism and chronic diarrhoea) that have not
been recorded in other RTHa cases [19]. Studies showed impaired function and dominant negative
activity of N359Y mutant TRa1, with some weakening of dominant negative activity of N359Y mutant
a2, particularly when coexpressed with normal TRb1. T3 treatment in the patient suppressed TSH and
raised energy expenditure and SHBG levels; paradoxically, unlike other RTHa cases, her heart rate
increased and diarrhoeaworsened [19]. Although conventional andwhole exome sequencing ruled out
abnormalities in other candidate genes, it is not certain whether all the clinical features of this case are
attributable solely to the N359Y THRA defect [24].
Whole genome sequencing in human autism spectrum disorder has identiﬁed a patient with a de
novo, missense, variant (R384C) in TRa1 [20]. This aminoacid change is almost certainly pathogenic,
being functionally deleteriouswhen studied in the context of murine TRa1 [9]. Interestingly, transgenic
mice harboring this mutation exhibit locomotor (ataxia) and behavioural abnormalities (anxiety,
depression) which can be alleviated by thyroid hormone treatment initiated even in adulthood [25,26].
Pathogenesis
Many clinical features in RTHa are typical of uncorrected hypothyroidism in childhood or adult
life. Patent cranial sutures, delayed dentition, femoral epiphyseal dysgenesis (disordered, endo-
chondral ossiﬁcation) and wormian bones (disordered, intramembranous ossiﬁcation) are recognized
features of childhood thyroid hormone deﬁciency [27,28]; macrocephaly may reﬂect delayed fonta-
nelle closure and hypothyroid facies includes a ﬂattened nasal bridge; such skeletal dysplasia is
associated with growth retardation (predominantly lower segmental) and delayed bone age in
childhood or adult short stature. Similarly, diminished colonic motility resulting in slow-transit
constipation with colonic dilatation (megacolon) or even ileus are reported in human hypothyroid-
ism [29]. Skeletal abnormalities (growth retardation, delayed tooth eruption, patent cranial sutures,
epiphyseal dysgenesis) and intestinal dysmotility in human RTHa are recapitulated in mutant TRa1
mutant mouse models [11,30].
Although borderline, the biochemical abnormalities found in RTHa cases (disproportionately
raised/high-normal T3 and low/low-normal T4 levels, resulting in a markedly reduced T4/T3 ratio
together with low rT3 levels in some cases) may reﬂect altered metabolism of thyroid hormones in
these patients. One possibility is that, as has been documented in mice with a dominant negative TRa1
mutation (TRa1-PV) [10], increased hepatic DIO1 levels augment T4 to T3 conversion; alternatively,
reduced tissue levels of DIO3, whose expression is TRa1 regulated [31], may contribute to these ab-
normalities with decreased inner-ring deiodination of T4 to rT3 and T3 to T2.
DIO3 is also expressed in skin and inhibition of the enzyme in this tissue enhances keratinocyte
proliferation in mice [32]. Accordingly, it is tempting to speculate that cutaneous DIO3 deﬁciency in
RTHa patients might, at least in part, mediate propensity to excess skin tags and moles.
Anaemia in RTHa patients correlates with documented abnormal erythropoiesis and reduced
haematocrit in TRa null or mutant mice [33,34]. Normal haematinics in patients suggests defective
C. Moran, K. Chatterjee / Best Practice & Research Clinical Endocrinology & Metabolism 29 (2015) 647e657654proliferation or differentiation of erythroid progenitors, with the mechanism remaining to be
elucidated.
Idiopathic epilepsy which was noted in one human case [16] correlates with heightened suscep-
tibility to seizures following photic [11] or audiogenic [25] stimulation and aberrant development of
GABAergic inhibitory interneurons [35] in mutant mice harbouring different TRa1 mutations.
Following thyroxine treatment in physiological dosage, tissues of RTHa patients exhibit variable
responses: thus, TSH levels suppress readily, implying preserved sensitivity within the hypothal-
amicepituitaryethyroid axis; conversely, cardiac parameters, resting energy expenditure and muscle
CK levels are less responsive [16,17]. Overall, these observations are consonant with thyroid hormone
resistance in organs (e.g. myocardium, skeletal muscle, gastrointestinal tract) expressing predomi-
nantly TRa1, with preservation of TH sensitivity in TRb-expressing tissues (hypothalamus, pituitary,
liver) (Fig. 3).Treatment
Thyroxine therapy raises metabolic rate, serum IGF1 and SHBG and lowers elevated LDL cholesterol
and muscle creatine kinase levels [13,15e17]; these changes may limit weight gain, especially in older
patients. In the childhood case we ﬁrst described [13], ﬁve years of thyroxine therapy has been clearly
beneﬁcial, improving overall height and subischial leg length, alleviating constipation (with associated
restoration of contractile activity in colonic manometry) and improving wellbeing (Moran & Chat-
terjee, unpublished observations). Low-normal IGF1 levels prompted the addition of growth hormone
to thyroxine therapy in another childhood case [15], but with little further improvement in growth.
Treatment from early childhood in cases harbouring mutant TRa1 whose dysfunction is reversible at
higher TH levels might have ameliorated their phenotype [17]. In adult life, these individuals reportFig. 3. Summary of the major tissue actions of thyroid hormone, together with the receptor subtypes mediating these effects. In
RTHa, tissues expressing mainly TRa would be resistant to thyroid hormone action with TRb-expressing tissues being sensitive.
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published observations). In contrast, in most cases, anaemia persists following thyroxine therapy; and,
relative to the rise in TH levels, changes in cardiac parameters (e.g. heart rate, indices of myocardial
contractility) are blunted [16,17].
Following thyroxine treatment, TSH levels suppress readily with elevation of FT3 to supra-
physiologic levels; serum SHBG may rise further from high-normal baseline levels [13] and
biochemical markers of bone turnover became progressively elevated in one case [16]. These ob-
servations raise the possibility that chronic, excess TH exposure in thyroxine-treated RTHa patients
might lead to unwanted toxicities in normal TRb-containing tissues. In this regard, future therapies
which could be developed include TRa1-selective thyromimetics [36], to selectively activate either
residual, normal TRa1 or partially defective, mutant TRa1 and overcome resistance in TRa-expressing
tissues.
As described above, many THRA defects in RTHa abrogate hormone binding to receptor, such that
dominant negative inhibition exerted by mutant TRa1 in vitro or in patient's cells studied ex vivo is
irreversible, even following exposure to high T3 levels. Here, developing small molecules which either
inhibit TR interactionwith the corepressor complex or its histone deacetylase enzymatic activity, might
represent a rational therapeutic approach. Supporting this notion, introduction of a mutation in NCoR
that abrogates its interaction with TR [37] or administration of suberoylanilide hydroxamic acid, an
inhibitor of histone deacetylase [38], ameliorates phenotypic abnormalities (growth, bone develop-
ment) in the murine TRa1-PV mutant model of RTHa.
Summary and conclusions
RTHa, a dominantly-inherited or sporadic disorder, due to heterozygous THRA mutations affecting
TRa1 alone or in combination with variant a2 protein, is characterised by clinical, biochemical and
physiological features of hypothyroidism in speciﬁc tissues, together with subtle abnormalities (low
T4/T3 ratio, variably reduced rT3) of thyroid function. Preliminary experience suggests that thyroxine
therapy is beneﬁcial.
Given the estimated prevalence (~1 in 40,000) of RTHb, with over 160 different TRbmutations being
recorded hitherto, it is highly likely that RTHa is more common but not fully ascertained, either because
the disorder lacks a clearcut, diagnostic signature of biochemical abnormalities or is associated with
unexpected phenotypes (e.g. autism spectrum disorder). In this context, it is interesting to note that
interrogation of databases (e.g. ExAC, 60,000 Exomes) reveals at least 101 non synonymous variants in
THRA (52 common to TRa1/a2; 3 TRa1-speciﬁc; 49 a2-speciﬁc); at least ﬁve variants are potentially
damaging, with aminoacid changes in codons that are homologous to residues in TRb known to be
mutated in association with RTHb (http://exac.broadinstitute.org/gene/ENSG00000126351).
The discovery of additional biomarkers in RTHa would be useful. Speciﬁcally, the discovery of a
combination of abnormal metabolites and/or proteins which can constitute a speciﬁc diagnostic test,
would enable more complete ascertainment of the disorder, with earlier commencement of TH
treatment in cases being potentially more effective. Furthermore, during TH therapy, markers which
better indicate correction of resistance in TRa-expressing tissues or toxicity in TRb-containing organs
would be of utility.Practice points
 Growth retardation, macrocephaly, skeletal dysplasia and constipation are common clinical
findings in TRa-mediated Resistance to thyroid hormone (RTHa).
 Biochemical abnormalities include low T4/T3 ratio, subnormal reverse T3, raised muscle
creatine kinase and anaemia.
 Thyroxine therapy reverses hypothyroidism in hormone-resistant TRa target tissues and is of
symptomatic benefit. However, careful monitoring for adverse sequelae of excessive TH
exposure in hormone-sensitive TRb tissues, is warranted.
Research agenda
 Is RTHa more prevalent than currently known and could it be associated with unexpected
clinical phenotypes?
 Can circulating biomarkers, which enable specific diagnosis of the disorder or guide TH
therapy, including preventing unwanted toxicity in TRb-expressing tissues, be developed?
 Can hormone resistance and dominant negative inhibition in selected target tissues be
modelled in mutation-containing, patient-derived cells (either primary or derivatives of
inducible pluripotent stem cells) studied ex vivo?
 Can TRa1 isoform-selective agonists be developed. Alternatively can transcriptional
repression by mutant TRa1 be relieved by developing agents which either dissociate mutant
receptor from the corepressor complex or inhibit its histone deacetylase activity?
 Can earlier (possibly antenatal) diagnosis, together with therapeutic intervention, prevent the
skeletal and neurocognitive deficits in this disorder?
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